Crohn's disease trials recruiting in Indiana

All Crohn's disease trials nationally

Cities in Indiana

Recruiting trials in Indiana

• A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
  NCT06663332 · Phase: Phase 3 · Ages: 3 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184944 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Indiana: New Albany
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
  NCT05923073 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
  NCT07196722 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
  NCT05509777 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
  NCT06227910 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT05442567 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
  NCT04779320 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
  NCT05995353 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819878 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Indiana: Indianapolis, New Albany
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Indiana: Indianapolis
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184931 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Indiana: New Albany
• Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
  NCT05781152 · Phase: Phase 4 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Indiana: Indianapolis
• Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
  NCT06332534 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Indiana: Indianapolis
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
  NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Indiana: Indianapolis, New Albany
• Precise Infliximab Exposure and Pharmacodynamic Control
  NCT05660746 · Phase: Phase 2, Phase 3 · Ages: 6 Years to 22 Years · Sex: All (male and female) · Indiana: Indianapolis
• Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
  NCT06548542 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Indiana: Indianapolis